Infants were protected against delta and, to some degree, omicron COVID-19 infections during the first 6 months of life when their mothers were immunized with
Reasons the bivalent COVID-19 vaccines have not shown a substantial advantage in research and clinical settings are explored in a Perspective article by Paul Offit,
Available for private purchase in Spain since 2015, the 4-component, protein-based meningococcal serogroup B vaccine (4CMenB; Bexsero) was effective in a case–control study for preventing invasive
Recipients of solid organ transplants (SOTs) had the highest risk of breakthrough infection (BI) when they had poorer antibody response (AbR) to SARS-CoV-2 vaccination, had
Testing whether SARS-CoV-2 vaccines can be adapted based on genetic sequences in variants that evade the immune response, investigators found that a candidate monovalent or
The 37 new chemical/biological entities approved by FDA during 2022 are discussed in an FDA Voices article published this week. Written by Patrizia Cavazzoni, director
Researchers report that 3 vaccine regimens against Zaire Ebola virus disease were safe and immunogenic, with immune responses evident from day 14 through month 12
The importance of better education and strong vaccine recommendations for parents of children with chronic kidney disease or primary hypertension is evident in a results
“The continued adverse effects of SARS-CoV-2 on individuals and populations necessitate the urgent development of the next generation of vaccines,” write FDA biologics chief Peter
In a study of outpatients with early COVID-19 in the setting of prevalent SARS-CoV-2 immunity and immune-evasive viral lineages, nirmatrelvir-ritonavir reduced the risk of hospitalization